Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis

Blood Coagulation and Fibrinolysis

Volumn 7, Issue 1, 1996, Pages 39-48

  Nicolini, F A ^a   Lee, P ^a   Malycky, J L ^a   Lefkovits, J ^a   Kottke Marchant, K ^a   Plow, E F ^a   Topol, E J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Coronary thrombosis; Hirudin; Thrombin; Thrombolysis; Tick anticoagulant peptide

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR 10A; FIBRINOLYTIC AGENT; FIBRINOPEPTIDE A; HIRUDIN; THROMBIN; THROMBIN ANTAGONIST; TICK ANTICOAGULANT PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029868652     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199601000-00005     Document Type: Article

References (33)

1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
2. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622.
3. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-1536.
4. Guccione MA, Kinlough-Rathbone RL, Packmam MA, et al. Effect of plasmin on rabbit platelets. Thromb Haemost 1985; 53: 8-14.
5. Torr SR, Nachowiak DA, Fujii S, Sobel BE. 'Plasminogen steal' and clot lysis. J Am Coll Cardiol 1992; 19: 1085-1090.
6. Eisenberg PR, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986; 7: 1255-1262.
7. Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 79: 980-989.
8. Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 1995; 91: 28-36.
9. Bloom AL. The release of thrombin from fibrin by fibrinolysis. Br J Hematol 1962; 82: 129-133.
10. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-3623.
11. Weitz JI, Huboda M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
12. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared to heparin in conjunction with tissue plasminogen activator and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 993-1003.
13. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing reocclusion. Circulation 1991; 83: 1048-1056.
14. Yasuda T, Gold HK, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb-IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-722.
15. Scully MF. Kinetic considerations on the physiologic control of thrombin and factor Xa. Sem Thromb Hemost 1992; 18: 218-223.
16. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-596.
17. Vlasuk GP, Ramjit D, Fujita T, et al. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 257-262.
18. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS. Anticoagulant efficacy of recombinant tick anticoagulant peptide, a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991; 84: 1741-1748.
19. Nicolini FA, Nichols WW, Saldeen TG, Mehta JL. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis. Cardiovasc Res 1991; 25: 283-289.
20. Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994; 89: 1802-1809.
21. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine, a model for in vivo evaluation of anti-thrombotic agents. Thromb Res 1980; 17: 841-853.
22. Mruk JS, Chesebro JH, Webster MWI, Heras M, Grill DE, Fuster V. Hirudin markedly enhances thrombolysis with rt-PA. Circulation 1990; 82: III-135 (abstract).
23. Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J Am Coll Cardiol 1993; 22: 296-301.
24. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute artery thrombosis. Circulation 1992; 85: 805-815.
25. Haaland AK, Skjønsberg OH, Gravem K, Ruyter R, Godal HC. Comparison of thrombin antithrombin (TAT) complex levels and fibrinopeptide A following thrombin incubation of human plasma using hirudin as an inhibitor of TAT formation. Thromb Res 1991; 61: 253-259.
26. Nicolini FA, Nichols WW, Saldeen TG, Khan S, Mehta JL. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis. Am Heart J 1992; 124: 280-288.
27. Folts JD, Gallagher K, Rowe GG. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? Circulation 1982; 65: 248-254.
28. Hisia J, Hamilton WP, Kleiman N, Roberts R, Chartman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-1437.
29. Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Superiority of selective factor Xa inhibition versus direct thrombin antagonism in facilitating rt-PA-induced thrombolysis in the canine model. Circulation 1993; 88: I-545 (abstract).
30. Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet 1990; 335: 481-482.
31. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-1637.
32. Antman ED, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90: 1624-1630.
33. Mann KG, Nesheim ME, Church WR, Halay P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.